INTRODUCTION
Molecular cytopathology features an increasing number and variety of tests with increasing breadth and depth, and this underscores the effective interplay between genomics and cytology. 1 Molecular cytopathology is especially relevant in lung cancer because most patients are diagnosed with cytological specimens. 2 Aspirated material is typically smeared directly onto glass slides, whereas the residual needle rinse is usually processed as a formalin-fixed, paraffinembedded (FFPE) cell block preparation. In the absence of an adequate cell block preparation, direct smears are the only source of tumor cells for mutation analysis, and they usually provide excellent-quality DNA. 2 Epidermal growth factor receptor (EGFR) testing can be performed successfully with both Diff-Quik-stained smears and Papanicolaou-stained smears. 2 Beyond EGFR, emerging predictive/prognostic genomic biomarkers, including Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral [v-ras] oncogene homolog (NRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA), are currently being tested for lung cancer patients. 3 Unfortunately, because of the increasing number of biomarkers that are needed for a comprehensive molecular characterization of lung cancer patients, this characterization is frequently difficult to perform with sequential single-gene mutational assays using the small amounts of DNA extracted from a cytological smear. Therefore, it is imperative that multigene mutational assays such as next-generation sequencing (NGS), which can simultaneously screen multiple genes with small amounts of DNA, be able to be performed on cytological smears. 4 Several recent studies have highlighted the use of NGS with cytological smears 2 ; however, the available data in the literature reflect only single-institution studies rather than multicenter experiences. Performing interlaboratory ring trials with cytological smears is difficult because smear slides are not reproducible or replaceable. Therefore, a wide interlaboratory comparison of mutation analysis protocols using cytological smears across institutions has not been performed. To fill this knowledge gap, we set up an international multicenter study involving 16 institutions in an interlaboratory ring trial. Each participating laboratory performed a multigene mutational assay that is typically used by the laboratory for routine clinical mutation testing. The mutational assays were performed in each of the clinical laboratories with the usual workflow, from tissue extraction to data analysis, for a set of quantitative cytological molecular reference slides. The reference slides were specifically designed as a surrogate for routine smears to harbor concurrent mutations in the EGFR, KRAS, NRAS, BRAF, and PIK3CA genes at various allele frequencies (AFs). Results were analyzed with respect to different testing methodologies, platforms, and assay validation parameters to assess the degree of reproducibility of multigene mutational assays.
MATERIALS AND METHODS

Experimental Design Overview
This international ring trial study was designed and coordinated by the University of Naples Federico II (Fed II; Fig. 1 ) per slide. Slides A, B, and C were prepared to harbor the previously described mutations at different dilution points (slide A, 10%; slide B, 5%; and slide C, 1%), whereas slide D represented parental wild-type cell lines. To ensure consistency for each slide produced, multigene reference slides were Diff-Quik-stained before scanning with NanoZoomer 3.0 (Hamamatsu, Hamamatsu City, Japan), which indicated a consistent and homogeneous distribution of cells between slides. The mutant AF was validated by HDx with digital polymerase chain reaction (dPCR) and by Fed II with NGS on an Ion Torrent platform (Thermo Fisher Scientific Inc, Waltham, Mass), as described in Supporting File 1 (see online supporting information). Interestingly, the mutation detection and the relative mutant AFs were similar among unstained reference slides, noncoverslipped, Diff-Quik-stained reference slides, and coverslipped, DiffQuik-stained reference slides (Table 1) .
After validation, sets of unstained and air-dried slides (A-D) were distributed to 16 different laboratories; those especially experienced in multigene testing of cytological samples 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] joined the working group of the annual meeting on molecular cytopathology held in Naples, Italy. Each laboratory conducted mutation testing on the reference slides with the usual multigene assay that it routinely used for testing clinical samples ( Table 2 ). All laboratory procedures, including internal quality control, were performed for the test slides in a fashion similar to that for any routine clinical samples. For the purpose of this multiinstitutional study, the analysis was focused on known hotspot mutations in the EGFR, KRAS, NRAS, BRAF, and PIK3CA genes. Additional genes harboring endogenous alterations that were detected as a result of using a variety of gene panels interrogating different genes by the various institutions were excluded from this study. Participating institutions provided in 10 days the results for each single slide together with information on the DNA extraction procedure and genotyping methods. The results and the mutant AF data were unblinded and confirmed against HDx specifications.
Statistical Analysis
The statistical analysis was performed with the Matlab statistics toolbox (version 2008; MathWorks, Natick, Mass) for Windows (32-bit) . The data are presented as numbers and percentages for categorical variables, and continuous data are expressed as means and standard deviations unless otherwise specified (Supporting Table 2 [see online supporting information]). Levene's test for equality of variances was performed with consideration of laboratory percentages among gene mutations for every set of mutations.
To assess the variations in mutant AF data, we performed the heterogeneity test while taking into account only the mutant allele percentages provided by laboratories using NGS. For this purpose, the I 2 statistic was considered. It represents the percentage of observed total variation across percentages that is due to real heterogeneity rather than chance. It is calculated as follows:
where Q is Cochran's heterogeneity statistic and df is the degrees of freedom. Particularly negative values of I 2 are put equal to zero so that I 2 lies between 0% and 100%. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity. In addition, box plots were used to show the variability of laboratory percentages for every gene mutation in slides A, B, and C (Fig. 2) . Finally, we considered whether there were significant differences between the platforms (Supporting Table  3 [see online supporting information]). There were 2 platforms: Illumina, which was adopted by 4 laboratories (group 1), and the Ion Torrent Personal Genome Machine System, which was adopted by 7 laboratories (group 2). Fed II preliminary validation data (Table 1) were included in terms of mean percentages.
RESULTS
Multigene Sequencing Method Approaches
Mutation analysis results were received from 15 participating laboratories before the cutoff date. One laboratory produced an incomplete data set and was excluded from the analysis. Among the remaining 14 institutions, the most used platform was NGS (n 5 11 [79%]), with a majority of these laboratories (n 5 6) adopting a semiconductor sequencing-based assay. Five laboratories used the Ion Torrent Personal Genome Machine System (Thermo Fisher Scientific), whereas 1 laboratory used the Ion Proton System (Thermo Fisher Scientific; Fig. 1 ). All 6 laboratories using Ion Torrent platforms adopted commercial panels validated by Thermo Fisher Scientific, including the Ion AmpliSeq Cancer Hotspot panel (n 5 4) and the Oncomine solid tumor panel (n 5 2; Table 3 ). Four laboratories used Illumina platforms (Illumina, Inc, San Diego, Calif): the MiSeq platform was used by 3 institutions in combination with the manufacturer-validated commercial panels, the TruSight Tumor 26 kit (n 5 2) and the TruSight Tumor 15 kit (n 5 1), whereas 1 institution used the Illumina HiSeq 2500 sequencer in association with the OncoPanel (Table 3) . 10 Only 1 institution performed NGS with the 454 GS Junior platform (Roche Diagnostics, Mannheim, Germany; Table 3 ). Two of the 3 institutions that did not use NGS used matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) on the MassARRAY system (Agena Bioscience, Hamburg, Germany), and both used the Myriapod colon status and lung status panels (Diatech Pharmacogenetics, Jesi, Italy). Finally, 1 laboratory used an in-house-developed multiplex TaqMan reverse transcription-polymerase chain reaction (RT-PCR) assay in the presence of a peptide nucleic acid. This assay, however, covered the 4 hotspot mutations in EGFR, KRAS, NRAS, and BRAF but did not cover the PIK3CA c.3140A>G p.H1047R mutation.
Testing Performance
Slide A All laboratories successfully detected the 5 engineered mutations on slide A with the exception of 1 laboratory using a multiplex TaqMan RT-PCR assay that did not cover the PIK3CA hotspot mutation (laboratory 13; see the Materials and Methods section). Notably, all the laboratories using NGS yielded the expected AF data (10%) in agreement (P 5 .171) with the HDx dPCR assessment ( Fig. 2 and Supporting Table 3 ).
Slide B
Although there was a general consensus among the different institutions for slide A, the results for slide B highlight differences resulting from the various analytical sensitivities of the different platforms. All laboratories using NGS detected the 5 engineered mutations on slide B with the expected mutant AF data (5%) in concordance (P 5 .063) with the HDx dPCR assessment (Fig. 2 and Supporting Table 2 [see online supporting information]). In fact, the mean AFs plus or minus the standard deviation for each mutation by NGS were 5.33% 6 1.62% (EGFR c.2235_2249del p.E746_A750del), 5.13% 6 1.19% (KRAS c.35G>A p.G12D), 5.02% 6 0.74% (NRAS c.182A>T p.Q61L), 5.80% 6 0.77% (BRAF c.1799T>A p.V600E), and 5.95% 6 0.76% (PIK3CA c.3140A>G p.H1047R). No differences in mutant AFs were observed among laboratories using Illumina (group 1) and Ion Torrent methodologies (group 2; Fig. 3) . Only PIK3CA c.3140A>G p.H1047R slightly differed (P 5 .0383) between Illumina (5.25% 6 0.83%) and Ion Torrent (6.19% 6 0.30%; Supporting Table 3 [see online supporting information]). In contrast, the 2 laboratories using MALDI-TOF (laboratories 1 and 11) missed the NRAS c.182A>T p.Q61L and PIK3CA c.3140A>G p.H1047R mutations in slide B. In addition, laboratory 1 also missed BRAF c.1799T>A p.V600E. In terms of estimating mutant AFs, MALDI-TOF overestimated the AFs for all genes: EGFR c.2235_2249del p.E746_A750delELREA was detected at a 12% AF by laboratory 1 and at a 20% AF by laboratory 11, KRAS c.35G>A p.G12D was detected at a 12% AF by laboratory 1 and at a 10% AF by laboratory 11, and BRAF c.1799T>A p.V600E was detected at a 10% AF by laboratory 11. The multiplex TaqMan RT-PCR assay (laboratory 13) detected all covered engineered mutations on slide B (Table 3) .
Slide C
Although for slide B there was a general agreement between the different institutions using NGS, the results derived for slide C underscored significant differences not only in the platform analytic sensitivity but also in variant calling modalities. Three laboratories using NGS (laboratories 7, 8, and 12) were unable to detect any mutation because their validated bioinformatic pipeline had a variant calling threshold set at 5%. The remaining laboratories were able to detect low-level mutations, although it was below the reportable threshold of variant calls. Three laboratories (laboratories 5, 10, and 14) were able to detect 3 of the 5 mutations, whereas 2 laboratories (laboratories 2 and 3) detected 4 of the 5 mutations (Table 3) . Only 3 laboratories (laboratories 4, 6, and 9) successfully detected all 5 engineered mutations ( Table 3 ). The mean AFs plus or minus the standard deviation for each mutation by NGS were 1.24% 6 0.35% (EGFR c.2235_2249del p.E746_A750del), 1.10% 6 0.34% (KRAS c.35G>A p.G12D), 1.12% 6 0.33% (NRAS c.182A>T p.Q61L), 1.34% 6 0.44% (BRAF c.1799T>A p.V600E), and 0.96% 6 0.08% (PIK3CA c.3140A>G p.H1047R). Thus, all mutations detected by NGS yielded the expected mutant AF data (1%) in agreement with the HDx dPCR assessment. A comparison of group 1 and group 2 was not performed for slide C because of the limited available data ( Fig. 3 and Supporting Table 3 [see online supporting information]). The 2 laboratories using MALDI-TOF (laboratories 1 and 11) failed to identify any of the mutations, but they were detected by an orthogonal real-time polymerase chain reaction assay in laboratory 1 (data not shown), and this emphasizes the inherent lower sensitivity of the MALDI-TOF assay in comparison with the NGS platform. In contrast, the multiplex TaqMan RT-PCR assay (laboratory 13) detected all covered engineered mutations on slide C (Table 3) . Because AFs were in significant discordance with the HDx dPCR assessment, after the cutoff data, laboratory 13 reanalyzed the residual DNA with respect to slides A to D with the GeneReader NGS platform (Qiagen, Valencia, Calif), and the results were similar to those revealed by the manufacturer and the other NGS platforms (Supporting Table 4 [see online supporting information]).
Slide D
All laboratories correctly genotyped slide D as the wild type, and there were no false-positive results. In addition, 13 of the 14 laboratories reported additional mutations in slides A to C because of the genetic background of the employed cell lines (available on request). For example, EGFR c.2155G>A p.G719S was detected with consistency (data not shown); however, because these endogenous mutations had not been validated by HDx, these mutations were not included in the assay comparisons.
DISCUSSION
In advanced lung cancer, the appropriate administration of targeted treatments or the eligibility for clinical trials requires tumor multigene mutational testing.
14 This should provide timely, accurate, and reliable results, even with small tissue specimens, including challenging cytological samples. Differences in gene panels, target enrichment strategies, and platforms are potential sources of inconsistent results, and methods to monitor the accuracy of multigene mutational testing are crucial. 20 To date, only histological samples have been included in proficiency testing panels because the quality of molecular testing with cytology is difficult to assess. 21 Ideally, interlaboratory ring trials should use routine clinical samples and evaluate both the pre-analytical parameters and the genotyping analysis. 22 FFPE sections from histological tissue blocks that can be distributed among laboratories make accurate interlaboratory comparisons possible. In contrast, cytological smears are unique specimen preparations that cannot be reproduced or replaced once they have been sacrificed for molecular testing. This inherent difficulty in using direct smears for testing, together with the need for additional validation, precludes the use of smears for mutation analysis in a large number of laboratories performing molecular assays. Some institutions digitally scan cytological smears before molecular testing to archive the cytomorphology of representative diagnostic microscopic fields to mitigate medicolegal constraints. 15, 23, 24 Moreover, the variety of cytological specimen preparations (eg, smears, cytospins, liquid-based preparations, and cell block preparations) and the heterogeneous mutational profile of clinical specimens with concurrent mutations present in various AFs and/or in subclonal populations of tumor cells represent significant challenges when it comes to using archival cytological smears for quality assurance purposes. 23 Conversely, to compare the performances of different methodologies, identical routine pre-analytical and genotyping procedures need to be replicated with standardized artificial reference standards. Certainly, control material should be highly reproducible and mimic clinical specimens as closely as possible. 25 To this end, previous studies have validated engineered cell lines in paraffin-embedded curls and sections. 5, 26, 27 In this study, to mirror a cytological smear, for the first time, we have developed and validated a cytological molecular reference slide set. A panel of clinically relevant mutations in lung cancer, including both deletion and point mutations (ie, mutations in EGFR as well as emerging predictive/prognostic mutational biomarkers such as KRAS, NRAS, BRAF, and PIK3CA) was engineered into cell lines specifically for this study. As a proof of principle, prototype slides were preliminarily tested; a fixed number of cells (2 3 10 6 ) were prepared for each slide, and this led to a homogeneous distribution of cells, as observed on Diff-Quik-stained slides (Fig. 1) . In all institutions joining this study, the multigene mutational methods were robust and accurate. Our results indicate that the performance of the NGS assays across different laboratories was excellent, regardless of the platform or gene panel used, with concordance for all 5 engineered mutations at 10% and 5% dilution points. In addition, NGS assays were able to accurately estimate the mutant AF, and this was consistent with the dPCR assessment performed at the source. In contrast, both laboratories adopting MALDI-TOF reported false-negative results at the 5% dilution point and a less than accurate estimation of the mutant AF. Notably, the performance of NGS among institutions in the low mutant AF setting (1%; slide C) showed lower concordance because of the use of different thresholds for variant calling, with some laboratories relying solely on the variant calls made by the bioinformatic pipelines and the set threshold, whereas others supplemented the variant calling with visual inspections of the sequencing reads. Our data showed that laboratory performance was not influenced by the types of mutations (deletions vs point mutations). The publication of recent guidelines establishing consensus standards for somatic mutation diagnostic testing, specifically for identifying and reporting mutations in solid tumors, may lead to a more uniform approach in reporting mutations below the threshold of 5%. 28, 29 Additional studies are needed by the Molecular Cytopathology Meeting Group to optimize quantitative cytological molecular reference slides that will better represent actual clinical cytological samples. Although Diff-Quik-or Papanicolaou-stained smears better reflect clinical routine samples, the mutation detection and relative mutant AFs were similar among unstained reference slides, noncoverslipped, Diff-Quik-stained reference slides, and coverslipped, Diff-Quik-stained reference slides in our preliminary validation study (Table 1) . Finally, a follow-up ring trial study is currently underway by the group to optimize and compare results with less cellular reference slides to simulate real-life molecular testing conditions for paucicellular smears. [30] [31] [32] 
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